Erratum: A real world multicenter retrospective study on extramedullary disease from Balkan Myeloma Study Group and Barcelona University: Analysis of parameters that improve outcome (Haematologica (2020) 10:51 (201-208) DOI: 10.3324/haematol.2019.219295)

Abstract

We have noticed an error in the progression-free survival of patients with extramedullary plasmacytoma in our article published in Haematologica in January 2020 (doi: HAEMATOL/2019/219295). The following sentence in the abstract: “Extramedullary plasmacytoma at relapse had the worst prognosis with a PFS of 13.6 months and overall survival of 11.4 months.” Should be replaced by: “Extramedullary plasmacytoma at relapse had the worst prognosis with a PFS of 9.1 months and overall survival of 11.4 months.” Likewise, on page 205, the following sentence: “However, if diagnosed at relapse, PFS and OS were 13.6 months and 11.4 months for EMP compared to 20.9 months (P=0.249) and 39.8 months (P=0.093) for PO, respectively (Table 2 and Figure 1).” Should be replaced by: “However, if diagnosed at relapse, PFS and OS were 9.1 months and 11.4 months for EMP compared to 20.9 months (P=0.249) and 39.8 months (P=0.093) for PO, respectively (Table 2 and Figure 1).” The error was also present in Table 2. The corrected Table 2 is shown below. © 2021 Ferrata Storti Foundation